Yeda Research and Develpment & Co. Ltd

Medical Research Council

Other

University of Washington

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Dan S Tawfik

Andrew David Griffiths

Sarel Fleishman

Israel Silman

Joel L Sussman

Yaacov Ashani

Amir Aharoni

Moshe Goldsmith

Leonid Gaydukov

Adi Goldenzweig

David Baker

Philippe Marliere

Zelig Eshhar

Armin Sepp

Sagar D Khare

Gustav Oberdorfer

Nidhi Aggarwal

Arren Bar-Even

Izhack Cherny

Tobias Erb

Per Jr Greisen

Rinkoo Devi Gupta

Bernard S Green

Steffen Lindner

Haim Leader

Andrew Université Louis Pasteur Cnrs Umr 7006 Griffiths

Andrew Instde Science Et d`Ingenierie Supramoleculaires Griffiths

Armin c/o Domantis Limited Sepp

The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate,) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO. The present invention further relates to the use of an organism, tissue, cell or organelle of the invention for enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO.

Carbon-neutral and carbon-positive photorespiration bypass routes supporting higher photosynthetic rate and yield

A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.

Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.

Stable proteins and methods for designing same

Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes.

PON polypeptides, polynucleotides encoding same and compositions and methods utilizing same

An isolated polypeptide comprising the amino acid sequence of serum paraoxonase (PON1) having catalytic efficiency of k/K&#x2248;10-5&#xb7;10Mminfor a G-type organophosphate.

Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same

The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising of the steps of: compartmentalizing genetic elements into microcapsules; expressing the genetic elements to produce their respective gene products within the microcapsules; sorting the genetic elements which produce the gene product having a desired activity. The invention enables the in vitro evolution of nucleic acids by repeated mutagenesis and iterative applications of the method of the invention.

In Vitro sorting method

The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.

Optical sorting method

Method for screening catalytic non-enzyme polypeptides and proteins

Growing community of inventors

Jerusalem, Israel

Dan S Tawfik